secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2026-07-17T20:15:14+00:00
Accession:  0001213900-26-079176
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics CMO James J. Ferguson III resigns effective July 31, 2026
-------------------------------------------------------------------------------

- CMO James J. Ferguson III resigned; effective July 31, 2026.
- Company is conducting a search for replacement.
- Separation agreement includes salary through separation date and COBRA premium payments for 6 months.
- Agreement includes general release of claims and non-disparagement clause.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026079176/0001213900-26-079176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026079176/ea0298082-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-079176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer